Blepharitis epidemiology and demographics
|
Blepharitis Microchapters | |
|
Diagnosis | |
|---|---|
|
Treatment | |
|
Case Studies | |
|
Blepharitis epidemiology and demographics On the Web | |
|
American Roentgen Ray Society Images of Blepharitis epidemiology and demographics | |
|
Risk calculators and risk factors for Blepharitis epidemiology and demographics | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mehrsefat, M.D. [2]
Overview
Blepharitis is one of the most common ocular disorders encountered in clinical practice and affects more than 180 million people in the United States.
Epidemiology and Demographics
Prevalence
Blepharitis is one of the most common ocular disorders encountered by eye care practitioners.[1] In the United States, blepharitis is estimated to affect more than 180 million people.[2] In a United States survey of ophthalmologists and optometrists, it was estimated that 37% and 47% of the patients presented with certain form of blepharitis in clinical practice, respectively.[3]
incidence
The true incidence of blepharitis remains undetermined.
Age
- A single-center study of 90 patients with chronic blepharitis reported a mean age of 50 years.[7]
- Staphylococcal blepharitis commonly affects younger population; the median age at diagnosis is 42 years.[8][9]
Gender
Race
- Blepharitis can affect all ethnic groups.[12][13][14]
- The incidence of chronic blepharitis increase with age. It commonly affects individuals older than 50 years of age.[15]
- There is no racial predilection for blepharitis.
References
- ↑ Macsai MS (2008). "The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis)". Trans Am Ophthalmol Soc. 106: 336–56. PMC 2646454. PMID 19277245.
- ↑ Guttman, C. (2009). Recent surveys draw attention to blepharitis. Ophthalmology Times, 34(15), 30-31.
- ↑ Lemp MA, Nichols KK (2009). "Blepharitis in the United States 2009: a survey-based perspective on prevalence and treatment". Ocul Surf. 7 (2 Suppl): S1–S14. PMID 19383269.
- ↑ Lindsley K, Matsumura S, Hatef E, Akpek EK. Interventions for chronic blepharitis. Cochrane Database Syst Rev. 2012;5:CD005556.
- ↑ Pflugfelder SC, Karpecki PM, Perez VL. Treatment of blepharitis: recent clinical trials. Ocul Surf. 2014;12(4):273-84.
- ↑ Lemp MA, Nichols KK. Blepharitis in the United States 2009: a survey-based perspective on prevalence and treatment. Ocular Surface 2009;7(Suppl 2):S1–14.
- ↑ McCulley JP, Dougherty JM, Deneau DG. Classification of chronic blepharitis. Ophthalmology 1982;89:1173-80.
- ↑ McCulley JP, Dougherty JM, Deneau DG. Classification of chronic blepharitis. Ophthlamology 1982;89:1173-80.
- ↑ McCulley JP, Dougherty JM. Blepharitis associated with acne rosacea and seborrheic dermatitis. International Ophthalmology Clinics 1985;25(1):159–72.
- ↑ McCulley JP, Dougherty JM, Deneau DG. Classification of chronic blepharitis. Ophthlamology 1982;89:1173-80.
- ↑ McCulley JP, Dougherty JM. Blepharitis associated with acne rosacea and seborrheic dermatitis. International Ophthalmology Clinics 1985;25(1):159–72.
- ↑ Lindsley K, Matsumura S, Hatef E, Akpek EK. Interventions for chronic blepharitis. Cochrane Database Syst Rev. 2012;5:CD005556.
- ↑ Pflugfelder SC, Karpecki PM, Perez VL. Treatment of blepharitis: recent clinical trials. Ocul Surf. 2014;12(4):273-84.
- ↑ Lemp MA, Nichols KK. Blepharitis in the United States 2009: a survey-based perspective on prevalence and treatment. Ocular Surface 2009;7(Suppl 2):S1–14.
- ↑ Schaumberg DA, Nichols JJ, Papas EB, et al. The International Workshop on Meibomian Gland Dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGD. Invest Ophthalmol Vis Sci 2011;52:1994-2005.